Global Next-Generation Tumor Genetic Testing Supply, Demand and Key Producers, 2024-2030

Global Next-Generation Tumor Genetic Testing Supply, Demand and Key Producers, 2024-2030

The global Next-Generation Tumor Genetic Testing market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

This report studies the global Next-Generation Tumor Genetic Testing demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Next-Generation Tumor Genetic Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Next-Generation Tumor Genetic Testing that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Next-Generation Tumor Genetic Testing total market, 2019-2030, (USD Million)

Global Next-Generation Tumor Genetic Testing total market by region & country, CAGR, 2019-2030, (USD Million)

U.S. VS China: Next-Generation Tumor Genetic Testing total market, key domestic companies and share, (USD Million)

Global Next-Generation Tumor Genetic Testing revenue by player and market share 2019-2024, (USD Million)

Global Next-Generation Tumor Genetic Testing total market by Type, CAGR, 2019-2030, (USD Million)

Global Next-Generation Tumor Genetic Testing total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Next-Generation Tumor Genetic Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Next-Generation Tumor Genetic Testing market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Next-Generation Tumor Genetic Testing Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Next-Generation Tumor Genetic Testing Market, Segmentation by Type
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Microarray Technology
Serum Proteomics
Nucleic Acid Sequencing

Global Next-Generation Tumor Genetic Testing Market, Segmentation by Application
Hospitals
Speciality Clinics
Research Institutes
Diagnostics Laboratories
Biopharmaceutical Companies

Companies Profiled:
Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics

Key Questions Answered

1. How big is the global Next-Generation Tumor Genetic Testing market?

2. What is the demand of the global Next-Generation Tumor Genetic Testing market?

3. What is the year over year growth of the global Next-Generation Tumor Genetic Testing market?

4. What is the total value of the global Next-Generation Tumor Genetic Testing market?

5. Who are the major players in the global Next-Generation Tumor Genetic Testing market?